ClinicalTrials.gg
RecruitingNCT06540703Updated Apr 23, 2026

Ketogenic Diet and Brain Response in Anorexia Nervosa

An interventional study of Therapeutic Ketogenic Diet (TKD) in Anorexia Nervosa, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Anorexia Nervosa by University of California, San Diego — 5 open to participants now, 7 under way, none of them phase 3. Anorexia Nervosa · University of California, San Diego.

Planned enrollment
4th of 14
90 · median 35
Started
2024
with 1 other
No phase
11 of 19
3 open now
Registered
17th of 19
by date

Among the 19 studies in Anorexia Nervosa by University of California, San Diego, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 17th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

5 of the 19 studies in Anorexia Nervosa by University of California, San Diego are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Anorexia Nervosa by University of California, San Diego, or all of them as a file.
02

Study summary

This is a longitudinal study with an open design in weight recovered anorexia nervosa (wrAN) individuals. Healthy controls (HC) will also be assessed. Study participants will be carefully assessed and will have 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) scans for assessment of regional brain glucose uptake. The wrAN group will be compared to healthy controls. Participants in the wrAN group will then complete 14 weeks of therapeutic ketogenic diet (TKD). At the end of the TKD study, participants will have assessments and a second [18F]FDG and TMS/EEG scan. Study participants will be followed over six months after the intervention. This follow-up procedure will help determine whether symptom improvement will be stable or worsen in individuals who choose to continue or discontinue the TKD intervention. This will be a naturalistic follow-up.

Read the detailed description

Anorexia nervosa (AN) is a severe psychiatric disorder. However, neurobiological models and interventions to explain and treat the core characteristics of food restriction, feeling fat, and body size overestimation are lacking. While research has made progress in understanding brain function involved in AN pathophysiology, translating those results into biological therapies has been challenging. Studies have suggested that metabolic factors contribute to developing and maintaining AN pathophysiology. Specifically, brain glucose utilization and metabolism may be altered in AN, interfere with brain energy homeostasis, and contribute to illness development and maintenance. A small study indicated that ketosis might be therapeutic for AN core behaviors such as eating and shape concerns. In this application, the investigator will study individuals weight recovered from AN, establish biological targets as diet-related metabolic markers for AN (R61 phase), and replicate and link those targets to AN-specific behaviors (R33 phase). The weight recovered AN group will also be compared with a healthy control sample. The R61 Phase Specific Aim of the project is to establish target engagement for a therapeutic ketogenic diet (TKD) in AN after weight recovery and establish safety and tolerability. It is hypothesized that TKD will be associated with reduced brain glucose metabolism using [18F]fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET) (target engagement). Higher blood ketosis levels will be associated with a more significant reduction of the brain [18F]FDG glucose metabolism rate (dose dependency). It is hypothesized that TKD will be well tolerated, that participants will remain within the normal weight range (tolerability), and that study participants will be able to adhere to TKD as indicated by regular blood ketosis measurements (treatment fidelity). There will be an initial indication that TKD and associated biological measures correlate with behavioral measures derived from eating disorder-specific assessments.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Weight Recovered Anorexia Nervosa (wrAN)

  • Age 18-45 years old
  • Male and Female sexes
  • All ethnic backgrounds
  • History of restricting-type anorexia nervosa (AN) according to criteria
  • Weight recovered with a > 17.5 for at least one month at the time of study
  • Elevated eating disorder-relevant behaviors on the Eating Disorders Inventory-3 and the Eating Disorder Examination Questionnaire

Healthy Control Group

  • Age 18-45 years old
  • Male and Female sexes
  • All ethnic backgrounds
  • Normal lifetime BMI according to CDC

Exclusion criteria

Exclusion Criteria:

Weight Recovered Anorexia Nervosa (AN)

  • Current pregnancy or nursing (will have to agree to measures if sexually active)
  • Lifetime history of bipolar I disorder or psychosis
  • Current substance abuse or dependence in the past 3 months
  • Psychotic illness/other organic brain syndromes, dementia, somatization disorders or conversion disorders
  • History of significant head trauma
  • Indication of intellectual disability or autism spectrum disorder

Healthy Control Group

  • No lifetime psychiatric illness and in particular no eating disorder history
  • Not be taking medication, and will not have a first degree relative with an eating disorder.

No subject in either group will have or be

  • mental retardation or pervasive developmental disorder
  • organic brain syndrome
  • dementia
  • psychotic disorder
  • bipolar disorder
  • somatic symptom
  • conversion disorder
  • current alcohol or substance use disorder
  • indication of major medical illness including a history of seizure disorder
  • pregnant or nursing at the time of the study
  • a history of traumatic brain injury.
  • diabetes mellitus or other metabolic disorders that could worsen on a ketogenic diet
  • intracranial or any other metal object within or near the head that cannot be safely removed, excluding the mouth
  • implanted neurostimulators, intracardiac lines, or heart disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Therapeutic Ketogenic Diet

    Subjects will be placed on a therapeutic ketogenic diet (TKD) for a duration of 14 weeks.

    Dietary Supplement: Therapeutic Ketogenic Diet (TKD)

Interventions

  • Dietary supplementTherapeutic Ketogenic Diet (TKD)

    2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet

06

What researchers measure

Primary outcomes

  1. [18F]fluorodeoxyglucose (FDG) uptake

    To test whether TKD will be associated with reduced brain \[18F\]fluorodeoxyglucose (FDG) uptake

    Time frame: Difference in pre/post Therapeutic Ketogenic Diet PET/CT scans

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2029, 55 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 55 months is above that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 6, 2024
StartActual
Oct 2, 2024
Primary completionEst.
May 2029
CompletionEst.
Jan 2030
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06540703
Responsible party
Guido Frank (Professor, University of California, San Diego) — Principal investigator
First posted
Aug 6, 2024
Start date
Oct 2, 2024
Primary completion
May 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion